Arie Belldegrun

Kite Pharma Inc (NASDAQ: KITE) is preparing to launch Axi-Cel, a chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma patients, later this year. Kite is pursuing an FDA label for patients with relapsed, aggressive and non-transplant eligible forms of the disease, a group of...

Kite Pharma Inc (NASDAQ: KITE) recently announced that it will be partnering with bluebird bio Inc (NASDAQ: BLUE) to develop second-generation, T-cell receptor product candidates. Arie Belldegrun, Kite Pharma CEO, was recently on CNBC to shed some light on T-cell therapy the company is...